PA
RVMD icon

Parallel Advisors’s Revolution Medicines RVMD Stock Holding History

Parallel Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Buy
1,353
+791
+141% +$116K ﹤0.01% 1129
2026
Q1 		$54.7K Buy
562
+362
+181% +$36.6K ﹤0.01% 1946
2025
Q4 		$15.9K Buy
200
+102
+104% +$6.69K ﹤0.01% 2415
2025
Q3 		$4.58K Buy
98
+50
+104% +$1.96K ﹤0.01% 2815
2025
Q2 		$1.77K Sell
48
-463
-91% -$17.8K ﹤0.01% 3068
2025
Q1 		$18.1K Buy
511
+416
+438% +$16.9K ﹤0.01% 2194
2024
Q4 		$4.16K Buy
95
+54
+132% +$2.73K ﹤0.01% 2706
2024
Q3 		$1.86K Buy
41
+8
+24% +$348 ﹤0.01% 2911
2024
Q2 		$1.28K Buy
+33
New +$1.23K ﹤0.01% 2905
2023
Q4 		– Sell
-192
Closed -$5.32K – 3446
2023
Q3 		$5.32K Buy
+192
New +$5.7K ﹤0.01% 2484
2022
Q3 		– Sell
-13
Closed – – 3446
2022
Q2 		$0 Buy
+13
New +$253 ﹤0.01% 3305
2020
Q3 		– Sell
-22
Closed – – 2664
2020
Q2 		$0 Buy
+22
New +$692 ﹤0.01% 2674

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Parallel Advisors's RVMD Position: Q2 2026 in Review

Parallel Advisors increased its Revolution Medicines (RVMD) stake by 141% in Q2 2026, buying an estimated $116K and bringing the position to 1,353 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #1129.

Parallel Advisors first reported a position in RVMD in Q2 2020 and has held it in 12 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Parallel Advisors held 1,353 shares of Revolution Medicines worth $253K as of Q2 2026.
  • Parallel Advisors bought 791 Revolution Medicines shares in Q2 2026, an estimated $116K.
  • Revolution Medicines made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1129 holding.
  • Parallel Advisors first reported a position in Revolution Medicines in Q2 2020 and has held it in 12 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.